Lisa C. Schmitt

Lisa C. Schmitt

Auto-generated profile, based on publicly available information

Lisa C. Schmitt

Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart 70569, Germany

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 December 2015 in The EMBO Journal
Verified
Journal Article
Closed access
PDF file
MKMartin Köhler
Martin Köhler
MRMichael Röring
Michael Röring
BSBjörn Schorch
Björn Schorch
KHKatharina Heilmann
Katharina Heilmann
NSNatalie Stickel
Natalie Stickel
TBTilman Brummer
Tilman Brummer

1 March 2013 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SDSumit Deswal
Sumit Deswal
AMAnja Meyer
Anja Meyer
GFGina J. Fiala
Gina J. Fiala
AEAnja E Eisenhardt
Anja E Eisenhardt
LSLisa C. Schmitt
Lisa C. Schmitt
WSWolfgang W A Schamel
Wolfgang W A Schamel
The activation kinetics of MAPK Erk are critical for T cell development and activation. In particular, sustained Erk signaling is required for T cell activation and effector functions, such as IL-2 production. Although Raf-1 triggers transient Erk activation, B-Raf is implicated in sustained Erk signaling after TCR stimulation. In this study, we show that B-Raf is dephosphorylated on its inhibitory serine 365 upon TCR triggering. However, it is unknown how B-Raf activation is coupled to the TCR. Using mass spectrometry, we identified protein kinase D–interacting substrate of 220 kDa (Kidins220)/ankyrin repeat-rich membrane spanning protein, mammalian target of rapamycin, Rictor, Dock2, and GM130 as novel B-Raf interaction partners. We focused on Kidins220, a protein that has been studied in neuronal cells and found that it associated with the pre-TCR, αβTCR, and γδTCR. Upon prolonged TCR stimulation, the Kidins220–TCR interaction was reduced, as demonstrated by immunoprecipitation and proximity ligation assays. We show that Kidins220 is required for TCR-induced sustained, but not transient, Erk activation. Consequently, induction of the immediate early gene products and transcription factors c-Fos and Erg-1 was blocked, and upregulation of the activation markers CD69, IL-2, and IFN-γ was reduced. Further, Kidins220 was required for optimal calcium signaling. In conclusion, we describe Kidins220 as a novel TCR-interacting protein that couples B-Raf to the TCR. Kidins220 is mandatory for sustained Erk signaling; thus, it is crucial for TCR-mediated T cell activation.

31 January 2018 in Oncotarget
Verified
Journal Article
Open access
PDF file
MHMeike Hutt
Meike Hutt
SFSina Fellermeier-Kopf
Sina Fellermeier-Kopf
OSOliver Seifert
Oliver Seifert
LSLisa C. Schmitt
Lisa C. Schmitt
KPKlaus Pfizenmaier
Klaus Pfizenmaier
RKRoland Kontermann
Roland Kontermann
Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells Targeting scFv-Fc-scTRAIL fusion proteins to tumor cells

3 April 2017 in mAbs
Verified
Journal Article
Closed access
LSLisa C. Schmitt
Lisa C. Schmitt
ARAlexander Rau
Alexander Rau
OSOliver Seifert
Oliver Seifert
JHJonas Honer
Jonas Honer
MHMeike Hutt
Meike Hutt
RKRoland Kontermann
Roland Kontermann
Human epidermal growth factor receptor 3 (HER3, also known as ErbB3) has emerged as relevant target for antibody-mediated tumor therapy. Here, we describe a novel human antibody, IgG 3-43, recognizing a unique epitope formed by domain III and parts of domain IV of the extracellular region of HER3, conserved between HER3 and mouse ErbB3. An affinity of 11 nM was determined for the monovalent interaction. In the IgG format, the antibody bound recombinant bivalent HER3 with subnanomolar affinity (KD = 220 pM) and HER3-expressing tumor cells with EC50 values in the low picomolar range (27 - 83 pM). The antibody competed with binding of heregulin to HER3-expressing cells, efficiently inhibited phosphorylation of HER3 as well as downstream signaling, and induced receptor internalization and degradation. Furthermore, IgG 3-43 inhibited heregulin-dependent proliferation of several HER3-positive cancer cell lines and heregulin-independent colony formation of HER2-overexpressing tumor cell lines. Importantly, inhibition of tumor growth and prolonged survival was demonstrated in a FaDu xenograft tumor model in SCID mice. These findings demonstrate that by binding to the membrane-proximal domains III and IV involved in ligand binding and receptor dimerization, IgG 3-43 efficiently inhibits activation of HER3, thereby blocking tumor cell growth both in vitro and in vivo.

18 July 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
YMYvonne Möller
Yvonne Möller
MMMarkus Morkel
Markus Morkel
JSJens Schmid
Jens Schmid
SBSven Beyes
Sven Beyes
JHJanina Hendrick
Janina Hendrick
MOMonilola A. Olayioye
Monilola A. Olayioye
Oncogenic Ras triggers hyperproliferation and impairs polarized colonic morphogenesis by autocrine ErbB3 signaling